Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Journal of Gastroenterology
Published in: Journal of Gastroenterology 9/2014

01-09-2014 | Original Article—Alimentary Tract

Novel risk factors for lymph node metastasis in early invasive colorectal cancer: a multi-institution pathology review

Authors: Hideki Ueno, Kazuo Hase, Yojiro Hashiguchi, Hideyuki Shimazaki, Shinji Yoshii, Shin-ei Kudo, Masafumi Tanaka, Yoshito Akagi, Takeshi Suto, Shinji Nagata, Keiji Matsuda, Koji Komori, Kazuhiko Yoshimatsu, Yasuhiko Tomita, Shozo Yokoyama, Eiji Shinto, Takahiro Nakamura, Kenichi Sugihara

Published in: Journal of Gastroenterology | Issue 9/2014

Login to get access

Abstract

Background

Novel risk factors for lymph node metastasis (LNM) in T1 colorectal cancer (CRC) have been recently proposed, but most have not been implemented because of the lack of validation. Here we determined the value of poorly differentiated clusters (PDCs) in a multi-institutional cohort of T1 CRC cases.

Methods

A pathology review involving 30 institutions was conducted for 3556 T1 CRCs. PDC was defined as malignant clusters comprising ≥5 cells and lacking a glandular formation. The ability to identify LNM risk was compared using Akaike’s information criterion (AIC).

Results

PDC was observed in 1401 tumors (39.4 %), including 94 (17.8 %) with <1000 µm submucosal invasion and 1307 (43.2 %) with ≥1000 µm submucosal invasion (P < 0.0001). The incidence of LNM was higher in PDC-positive tumors (17.4 %) than in PDC-negative tumors (6.9 %; P < 0.0001), and PDCs had an adverse impact on LNM irrespective of the degree of submucosal invasion. Grade 3, vascular invasion, budding, and submucosal invasion depth were also significant factors (all, P < 0.0001). AIC of risk factor to identify LNM risk was most favorable for vascular invasion (2273.4), followed by PDC (2357.4); submucosal invasion depth (2429.1) was the most unfavorable. Interinstitutional judgment disparities were smaller in PDC (kappa, 0.51) than vascular invasion (0.33) or tumor grade (0.48).

Conclusions

PDC is a promising new parameter with good ability to identify LNM risk. Use of its appropriate judgment criteria will enable us determine whether an observational policy can be safely applied following local tumor excision in T1 CRC cases.
Literature
1.
Repici A, Hassan C, Pessoa DDP, Pagano N, Arezzo A, Zullo A, et al. Efficacy and safety of endoscopic submucosal dissection for colorectal neoplasia: a systematic review. Endoscopy. 2012;44:137–47.PubMedCrossRef
2.
Kiriyama S, Saito Y, Yamamoto S, Soetikno R, Matsuda T, Nakajima T, et al. Comparison of endoscopic submucosal dissection with laparoscopic-assisted colorectal surgery for early-stage colorectal cancer: a retrospective analysis. Endoscopy. 2012;44:1024–30.PubMedCrossRef
3.
Lee EJ, Lee JB, Lee SH, Kim DS, Lee DH, Lee DS, et al. Endoscopic submucosal dissection for colorectal tumors-1000 colorectal ESD cases: one specialized institute’s experiences. Surg Endosc 2012 (Epub ahead of print).
4.
Cooper HS. Surgical pathology of endoscopically removed malignant polyps of the colon and rectum. Am J Surg Pathol. 1983;7:613–23.PubMedCrossRef
5.
Morson BC, Whiteway JE, Jones EA, Macrae FA, Williams CB. Histopathology and prognosis of malignant colorectal polyps treated by endoscopic polypectomy. Gut. 1984;25:437–44.PubMedCentralPubMedCrossRef
6.
7.
Sugihara K, Muto T, Morioka Y. Management of patients with invasive carcinoma removed by colonoscopic polypectomy. Dis Colon Rectum. 1989;32:829–34.PubMedCrossRef
8.
Cranley JP, Petras RE, Carey WD, Paradis K, Sivak MV. When is endoscopic polypectomy adequate therapy for colonic polyps containing invasive carcinoma? Gastroenterology. 1986;91:419–27.PubMed
9.
Coverlizza S, Risio M, Ferrari A, Fenoglio-Preiser CM, Rossini FP. Colorectal adenomas containing invasive carcinoma: pathologic assessment of lymph node metastatic potential. Cancer. 1989;64:1937–47.PubMedCrossRef
10.
Muller S, Chesner IM, Egan MJ, Rowlands DC, Collard MJ, Swarbrick ET, et al. Significance of venous and lymphatic invasion in malignant polyps of the colon and rectum. Gut. 1989;30:1385–91.PubMedCentralPubMedCrossRef
11.
12.
13.
Suh JH, Han KS, Kim BC, Hong CW, Sohn DK, Chang HJ, et al. Predictors for lymph node metastasis in T1 colorectal cancer. Endoscopy. 2012;44:590–5.PubMedCrossRef
14.
Hassan C, Zullo A, Risio M, Rossini FP, Morini S. Histologic risk factors and clinical outcome in colorectal malignant polyp: a pooled-data analysis. Dis Colon Rectum. 2005;48:1588–96.PubMedCrossRef
15.
Volk EE, Goldblum JR, Petras RE, Carey WD, Fazio VW. Management and outcome of patients with invasive carcinoma arising in colorectal polyps. Gastroenterology. 1995;109:1801–7.PubMedCrossRef
16.
Fielding LP, Phillips RKS, Hittinger R. Factors influencing mortality after curative resection for large bowel cancer in elderly patients. Lancet. 1989;18:595–7.CrossRef
17.
Boenicke L, Fein M, Sailer M, Isbert C, Germer C-T, Thalheimer A. The concurrence of histologically positive resection margins and sessile morphology is an important risk factor for lymph node metastasis after complete endoscopic removal of malignant colorectal polyps. Int J Colorectal Dis. 2010;25:433–8.PubMedCrossRef
18.
Benizri EI, Bereder J-M, Rahili A, Bernard J-L, Vanbiervliet G, Filippi J, et al. Additional colectomy after colonoscopic polypectomy for T1 colon cancer: a fine balance between oncologic benefit and operative risk. Int J Colorectal Dis. 2012;27:1473–8.PubMedCrossRef
19.
Schmoll HJ, Van Cutsem V, Stein A, Valentini V, Glimelius B, Haustermans K, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23:2479–516.PubMedCrossRef
20.
Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol. 2009;17:1–29.CrossRef
21.
Ueno H, Hashiguchi Y, Kajiwara Y, Shinto E, Shimazaki H, Kurihara H, et al. Proposed objective criteria for “grade 3” in early invasive colorectal cancer. Am J Clin Pathol. 2010;134:312–22.PubMedCrossRef
22.
Barresi V, Bonetti LR, Branca G, Gregorio CD, de Leon MP, Tuccari G. Colorectal carcinoma grading by quantifying poorly differentiated cell clusters is more reproducible and provides more robust prognostic information than conventional grading. Virchows Arch. 2012;461:621–8.PubMedCrossRef
23.
Ueno H, Shimazaki H, Shinto E, Hashiguchi Y, Nakanishi K, Maekawa K, et al. New criteria for histologic grading of colorectal cancer. Am J Surg Pathol. 2012;36:193–201.PubMedCrossRef
24.
Haggitt RC, Glotzbach RE, Soffer EE, Wruble LD. Prognostic factors in colorectal carcinomas arising in adenomas: implications for lesions removed by endoscopic polypectomy. Gastroenterology. 1985;89:328–36.PubMed
25.
Ueno H, Mochizuki H, Hashiguchi Y, Shimazaki H, Aida S, Hase K, et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology. 2004;127:385–94.PubMedCrossRef
26.
Akaike H. Information theory and an extension of the maximum likelihood principle. Budapest: Akademia Kiado; 1973.
27.
R Development Core Team. A language and environment for statistical computing. R. Foundation for Statistical Computing; 2006.
28.
Kudo S. Endoscopic mucosal resection of flat and depressed types of early colorectal cancer. Endoscopy. 1993;25:455–61.PubMedCrossRef
29.
Kikuchi R, Takano M, Takagi K, Fujimoto N, Nozaki R, Fujiyoshi T, et al. Management of early invasive colorectal cancer-risk of recurrence and clinical guidelines. Dis Colon Rectum. 1995;38:1286–95.PubMedCrossRef
30.
Suzuki T, Sadahiro S, Mukoyama S, Ishikawa K, Yasuda S, Tajima T, et al. Risk of lymph node and distant metastases in patients with early invasive colorectal cancer classified as Haggitt’s level 4 invasion. Dis Colon Rectum. 2003;46:203–8.PubMedCrossRef
31.
Tateishi Y, Nakanishi Y, Taniguchi H, Shimoda T, Uemura S. Pathological prognostic factors predicting lymph node metastasis in submucosal invasive (T1) colorectal carcinoma. Mod Pathol. 2010;23:1068–72.PubMedCrossRef
32.
Araki Y, Isomoto H, Shirouzu K, Miura K, Iwanaga H, Okita A, et al. Clinicopathological characteristics of colorectal submucosal carcinoma with lymph node metastasis. Kurume Med J. 1993;40:123–7.PubMedCrossRef
33.
Hase K, Shatney CH, Mochizuki H, Johnson DL, Tamakuma S, Vierra M, et al. Long-term results of curative resection of “minimally invasive” colorectal cancer. Dis Colon Rectum. 1995;38:19–26.PubMedCrossRef
34.
Egashira Y, Yoshida T, Hirata I, Hamamoto N, Akutagawa H, Takeshita A, et al. Analysis of pathological risk factors for lymph node metastasis of submucosal invasive colon cancer. Mod Pathol. 2004;17:503–11.PubMedCrossRef
35.
Liang P, Hong J-W, Ubukata H, Liu G, Katano M, Motohashi G, et al. Myofibroblasts correlate with lymphatic microvessel density and lymph node metastasis in early-stage invasive colorectal carcinoma. Anticancer Res. 2005;25:2705–12.PubMed
36.
Oh-e H, Tanaka S, Kitadai Y, Shimamoto F, Yoshihara M, Haruma K. Angiogenesis at the site of deepest penetration predicts lymph node metastasis of submucosal colorectal cancer. Dis Colon Rectum. 2001;44:1129–36.PubMedCrossRef
37.
Sakuragi M, Togashi K, Konishi F, Koinuma K, Kawamura Y, Okada M, et al. Predictive factors for lymph node metastasis in T1 stage colorectal carcinomas. Dis Colon Rectum. 2003;46:1626–32.PubMedCrossRef
38.
Kitajima K, Fujimori T, Fujii S, Takeda J, Ohkura Y, Kawamata H, et al. Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaboration study. J Gastroenterol. 2004;39:534–43.PubMedCrossRef
39.
40.
41.
Kaneko I, Shinji S, Oka S, Kawamura T, Hiyama T, Ito M, et al. Lymphatic vessel density at the site of deepest penetration as a predictor of lymph node metastasis in submucosal colorectal cancer. Dis Colon Rectum. 2006;50:13–21.CrossRef
42.
Kaneko I, Tanaka S, Oka S, Yoshida S, Hiyama T, Arihiro K, et al. Immunohistochemical molecular markers as predictors of curability of endoscopically resected submucosal colorectal cancer. World J Gastroenterol. 2007;28:3829–35.
43.
Yamauchi H, Togashi K, Kawamura Y, Horie H, Sasaki J, Tsujinaka S, et al. Pathological predictors for lymph node metastasis in T1 colorectal cancer. Surg Today. 2008;38:905–10.PubMedCrossRef
44.
Suzuki A, Togashi K, Nokubi M, Koinuma K, Miyakura Y, Horie H, et al. Evaluation of venous invasion by elastica van Gieson stain and tumor budding predicts local and distant metastases in patients with T1 stage colorectal cancer. Am J Surg Pathol. 2009;33:1601–7.PubMedCrossRef
45.
Komori K, Hirai T, Kanemitsu Y, Shimizu Y, Sano T, Ito S, et al. Is “depth of submucosal invasion >=1,000 mm” an important predictive factor for lymph node metastasis in early invasive colorectal cancer (PT1)? Hepatogastroenterology. 2010;57:1123–7.PubMed
46.
Nakadoi K, Tanaka S, Kanao H, Terasaki M, Takata S, Oka S, et al. Management of T1 colorectal carcinoma with special reference to criteria for curative endoscopic resection. J Gastroenterol Hepatol. 2012;27:1057–62.PubMedCrossRef
47.
Hamilton SR, Bosman FT, Boffetta P, Ilyas M, Morreau H, Nakamura S-I, et al. Carcinoma of the colon and rectum. In: Bosman FT, Carneiro F, Hruban RH, et al., editors. WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer (IARC); 2010. p. 134–46.
48.
Jass JR, O’Brien MJ, Riddell RH, Snover DC. Recommendations for the reporting of surgically resected specimens of colorectal carcinoma. Hum Pathol. 2007;38:537–45.PubMedCrossRef
49.
50.
51.
Kazama S, Watanabe T, Ajioka Y, Kanazawa T, Nagawa H. Tumour budding at the deepest invasive margin correlates with lymph node metastasis in submucosal colorectal cancer detected by anticytokeratin antibody CAM5.2. Br J Cancer. 2006;94:293–8.PubMedCentralPubMedCrossRef
52.
Ishikawa Y, Akishima-Fukasawa Y, Ito K, Akasaka Y, Yokoo T, Ishii T. Histopathologic determinants of regional lymph node metastasis in early colorectal cancer. Cancer. 2008;112:924–33.PubMedCrossRef
53.
Ogawa T, Yoshida T, Tsuruta T, Tokuyama W, Adachi S, Kikuchi M, et al. Tumor budding is predictive of lymphatic involvement and lymph node metastases in submucosal invasive colorectal adenocarcinomas and in non-polypoid compared with polypoid growths. Scand J Gastroenterol. 2009;44:605–14.PubMedCrossRef
54.
Horcic M, Koelzer VH, Karamitopoulou E, Terracciano L, Puppa G, Zlobec I, et al. Tumor budding score based on 10 high-power fields is a promising basis for a standardized prognostic scoring system in stage II colorectal cancer. Hum Pathol. 2012 (Epub ahead of print).
55.
Puppa G, Senore C, Sheahan K, Vieth M, Lugli A, Zlobec I, et al. Diagnostic reproducibility of tumour budding in colorectal cancer: a multicentre, multinational study using virtual microscopy. Histopathology. 2012 (Epub ahead print).
Metadata
Title
Novel risk factors for lymph node metastasis in early invasive colorectal cancer: a multi-institution pathology review
Authors
Hideki Ueno
Kazuo Hase
Yojiro Hashiguchi
Hideyuki Shimazaki
Shinji Yoshii
Shin-ei Kudo
Masafumi Tanaka
Yoshito Akagi
Takeshi Suto
Shinji Nagata
Keiji Matsuda
Koji Komori
Kazuhiko Yoshimatsu
Yasuhiko Tomita
Shozo Yokoyama
Eiji Shinto
Takahiro Nakamura
Kenichi Sugihara
Publication date
01-09-2014
Publisher
Springer Japan
Published in
Journal of Gastroenterology / Issue 9/2014
Print ISSN: 0944-1174
Electronic ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-013-0881-3

Other articles of this Issue 9/2014

Journal of Gastroenterology 9/2014 Go to the issue

Original Article—ALIMENTARY TRACT

Hematologic malignancies in the Japanese patients with inflammatory bowel disease

Original Article—Liver, Pancreas, and Biliary Tract

Increased adiponectin associated with poor survival in hepatocellular carcinoma

Original Article—Liver, Pancreas, and Biliary Tract

Frequent alteration of the protein synthesis of enzymes for glucose metabolism in hepatocellular carcinomas

Original Article—Liver, Pancreas, and Biliary Tract

Alcohol consumption and recurrence of non-B or non-C hepatocellular carcinoma after hepatectomy: a propensity score analysis

Letter to the Editor

Reply to the letter by E. Savarino et al. regarding “The placebo effect is a relevant factor in evaluating effectiveness of therapies in functional gastrointestinal disorders”

Original Article—Liver, Pancreas, and Biliary Tract

Occlusion of portosystemic shunts improves hyperinsulinemia due to insulin resistance in cirrhotic patients with portal hypertension
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits